Join our free Let’s Move Exercise Program! Accessible, expert-led virtual sessions to help you build strength and improve balance from home. REGISTER
Written by Jacen Emerson Edited by Juan Mato Repurposed steroid hormone prevents cell death and motor symptoms in animal models of SCA3 A New Treatment and Biomarker for SCA3? Duarte-Silva and colleagues in Portugal recently investigated a drug called tauroursodeoxycholic acid (TUDCA) in an effort to establish new treatments for Read More…
Written by Carrie Sheeler, PhD Edited by Celeste Suart, PhD Advances in wearable technology for tracking ataxia severity combine coordination changes across different types of movement. How do you know a new treatment is working? This is the key question that clinicians have to answer when developing and testing new therapies. One on one, a patient Read More…
Written by Poojashree Chettiar Edited by Pragya Goel, PhD AI and wearable tech may transform how ataxia is monitored Could everyday devices help track ataxia? Finding treatments for neurological disorders like spinocerebellar ataxias (SCAs) and multiple system atrophy (MSA-C) has been challenging. A major reason is the lack of good Read More…
Written by Jacen Emerson Edited by Hannah Shorrock, PhD Human Imaging data reveals worsening spinal cord damage in several Ataxias that can begin before symptoms start. Why does the spinal cord matter in SCA? Rezende and colleagues recently published the most thorough study of spinal cord damage in Spinocerebellar Ataxias Read More…
Escrito por Alexandra PutkaEditado por Dr Hannah K ShorrockTraducido por Ismael Araujo-Aliaga Científicos caracterizan la progresión de las enfermedades SCA1, 2, 3 y 6, y descubren que los síntomas cambian más rápido en los primeros 10 años de la enfermedad. El diseño de ensayos clínicos para enfermedades raras como las Read More…
Written by Ross Pelzel Edited by Eder Xhako, PhD and Celeste Suart, PhD Alternative splicing produces different versions of proteins that arise from the same gene. In many neurodegenerative diseases, this process results in dysfunctional proteins that lead to disease symptoms. In Shorrock et al., the authors investigate how alternative Read More…
Escrito por: Asmer Aliyeva Editado por: Dr. Hannah K Shorrock Traduzido por: Priscila Pereira Sena Tratamento com Oligonucleotídeo Antisenso (ASO, do inglês Antisense Oligonucleotide) melhora a função dos neurônios de Purkinje regulada por canais de potássio, e destaca a conectividade cerebral alterada na interrupção do movimento na SCA3. Entender quais tipos celulares Read More…
La Comunicación Aumentativa y Alternativa (CAA) es un término general que tiene muchos significados. En pocas palabras, la CAA es toda forma de comunicación distinta del habla. En esencia, la CAA utiliza símbolos. Para que un mensaje se considere una CAA, debe representarse simbólicamente. La CAA debe significar algo más. Read More…
Escrito por Asmer Aliyeva Editado por Dr. Hannah K Shorrock Traducido por BS Ismael Araujo-Aliaga El tratamiento con oligonucleótidos antisentido (ASO) mejora la función de las neuronas de Purkinje regulada por canales de potasio y resalta la conectividad cerebral alterada en el trastorno del movimiento en SCA3. Comprender qué tipos de células Read More…
Written by Alexandra Putka Edited by Dr Hannah K Shorrock Scientists characterize SCA1, 2, 3, & 6 disease progression, finding that symptoms change most rapidly in the first 10 years of the disease. Designing clinical trials for rare diseases such as spinocerebellar ataxias (SCAs) requires us to know the timeline Read More…
